Literature DB >> 8558665

The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.

S B Saxman1, C R Nichols, R S Foster, J E Messemer, J P Donohue, L H Einhorn.   

Abstract

PURPOSE: We reviewed our experience with patients who had nonseminomatous germ cell tumors clinically limited to the testis and persistently elevated serum human chorionic gonadotropin (HCG) or alpha-fetoprotein (AFP) levels after orchiectomy.
MATERIALS AND METHODS: All patients had clinical stage I disease with persistently elevated tumor markers that were not decreasing in accordance with the expected metabolic decay rate at retroperitoneal lymph node dissection.
RESULTS: Of 30 patients identified 3 had elevated AFP, 24 had elevated HCG and 3 had elevation of both markers. Of the 6 patients with elevated AFP with or without concurrent HCG elevation 5 (83%) had relapse and required chemotherapy, as did 6 of 24 (25%) with HCG elevation.
CONCLUSIONS: Patients with persistently elevated AFP after orchiectomy should be treated initially with chemotherapy. Although the majority of patients with elevated serum HCG were disease-free after surgery alone, a fourth of these patients still had relapse and required chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558665

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

2.  [Testicular cancer--is there an indication for adjuvant or neoadjuvant systemic therapy?].

Authors:  S Langenkamp; P Albers
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

3.  False elevation of human chorionic gonadotropin in a patient with testicular cancer.

Authors:  David J Gallagher; Jamie Riches; Dean F Bajorin
Journal:  Nat Rev Urol       Date:  2010-04       Impact factor: 14.432

4.  Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.

Authors:  Tomohiro Kawaguchi; Toshihiro Kumabe; Masayuki Kanamori; Ryuta Saito; Yoji Yamashita; Yukihiko Sonoda; Mika Watanabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2011-02-26       Impact factor: 4.130

Review 5.  Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors.

Authors:  Salim K Cheriyan; Marilin Nicholson; Ahmet M Aydin; Mounsif Azizi; Charles C Peyton; Wade J Sexton; Scott M Gilbert
Journal:  Transl Androl Urol       Date:  2020-01

6.  [The role of tumour markers in diagnosis and management of testicular germ cell tumours].

Authors:  S Krege; P Albers; A Heidenreich
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

7.  Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies.

Authors:  Gautam Jayram; Russell Z Szmulewitz; Scott E Eggener
Journal:  Indian J Urol       Date:  2010 Jan-Mar

8.  Current management of testicular cancer.

Authors:  Yu Seob Shin; Hyung Jin Kim
Journal:  Korean J Urol       Date:  2013-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.